Literature DB >> 21931135

Science to practice: can theranostic fullerenes be used to treat brain tumors?

Jeff W M Bulte1.   

Abstract

In an orthotopic brain tumor mouse model, it was shown that convection-enhanced intratumoral delivery of a theranostic metallofullerene (f-Gd₃N@C₈₀) labeled with lutetium 177 (¹⁷⁷Lu) and tetraazacyclododecane tetraacetic acid (DOTA) (¹⁷⁷Lu-DOTA-f-Gd₃N@C₈₀) increases median survival from 21 to 52 days, with a prolonged metallofullerene tumor retention that can be visualized with magnetic resonance (MR) imaging. © RSNA, 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21931135     DOI: 10.1148/radiol.11111636

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  2 in total

Review 1.  Assessing the barriers to image-guided drug delivery.

Authors:  Gregory M Lanza; Chrit Moonen; James R Baker; Esther Chang; Zheng Cheng; Piotr Grodzinski; Katherine Ferrara; Kullervo Hynynen; Gary Kelloff; Yong-Eun Koo Lee; Anil K Patri; David Sept; Jan E Schnitzer; Bradford J Wood; Miqin Zhang; Gang Zheng; Keyvan Farahani
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-10-31

Review 2.  Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.

Authors:  Nolan Ung; Isaac Yang
Journal:  J Neurooncol       Date:  2015-06-13       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.